Kodiak Sciences Inc

NASDAQ: KOD
$2.69
-$0.12 (-4.3%)
Closing Price on June 17, 2024

KOD Chart and Intraday Price

KOD Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 2631 HANOVER STREET, PALO ALTO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 315.36M USD
Shares Outstanding 52,472,000
Kodiak Sciences Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for retinal diseases. Its flagship product, tarcocimab tedromer, is making strides in clinical studies to address conditions like wet age-related macular degeneration and diabetic macular edema. Additionally, Kodiak is exploring treatments for inflammatory retinal diseases and dry AMD with its early-stage candidates. Founded in 2009 and evolving from Oligasis, LLC, Kodiak is based in Palo Alto, California, pushing the boundaries of retinal disease treatment.

KOD Articles

Tuesday's additional top analyst upgrades and downgrades included Cracker Barrel, Farfetch, Intel, Kodiak Sciences, Pinterest, Snowflake, Teladoc and more.
Friday's top analyst upgrades and downgrades included Dish Network, Dollar General, eBay, Gap, HollyFrontier, Mosaic, NetApp, Nextdoor, Skillz, Tesla, TJX, Toll Brothers and Vipshop.
Thursday afternoon's top analyst upgrades and downgrades included FuboTV, Grab, Infosys, Intel, Macy’s, Mattel and Under Armour.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Clorox, Clover Health Investments, Datadog, Electronic Arts, Etsy, General Motors, Intuitive Surgical,...
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Nielsen, Nordstrom, PayPal, StoneCo and more.